Skip to main content
BPH ENERGY LTD logo

BPH ENERGY LTD — Investor Relations & Filings

Ticker · BPH ISIN · AU000000BPH4 ASX Financial and insurance activities
Open in API
Filings indexed 1,483 across all filing types
Latest filing 2008-09-22 Regulatory Filings
Country AU Australia
Listing ASX BPH

About BPH ENERGY LTD

https://www.bphenergy.com.au/

BPH Energy Ltd is a diversified investment company focused on the commercialization of biomedical technologies and the exploration of energy resources. The company maintains a significant portfolio in the biotechnology sector, notably through its investment in Cortical Dynamics Ltd, which develops the Brain Anaesthesia Response Monitor (BARM) for objective measurement of anesthetic effect. In the energy sector, BPH Energy holds a substantial interest in Advent Energy Ltd, an unlisted oil and gas exploration company with assets including the PEP 11 permit in the offshore Sydney Basin. Additionally, the company has expanded its focus into sustainable energy through investments in Clean Hydrogen Technologies, which utilizes proprietary processes to produce turquoise hydrogen and solid carbon. BPH Energy aims to identify and develop high-growth opportunities within the healthcare and resource sectors to create long-term value.

Recent filings

Filing Released Lang Actions
HLS5 at BIO 2008 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 September 2008 from BioPharmica. It discusses progress in research and development related to the HLS5 gene, potential licensing opportunities, and commercial partnerships. There are no financial statements, no quarterly or annual financial data, no regulatory certifications, or voting results. The content is primarily a business update on research progress and commercialization efforts. The document length is 2714 characters, which is relatively short and does not contain detailed financial or regulatory information. It is not a report publication announcement since it does not mention any report being attached or published. It is not a call transcript, earnings release, or management report. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2008-09-22 English
CEO Appointment 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is an announcement dated 19 September 2008 from BioPharmica Limited regarding the appointment of Dr. Peter King as Chief Executive Officer. It provides biographical details about the new CEO and mentions the current Chairman and Managing Director. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no legal proceedings, no capital changes, and no other report types. The content clearly relates to a change in senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on management appointment, supporting this classification with high confidence.
2008-09-18 English
New Drug Cancer Impact 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 18 September 2008 from BioPharmica. It discusses new research progress on anti-cancer drug development, focusing on gene activation and preliminary lab results. There are no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, no capital or financing updates, and no legal or merger information. The document is a company announcement about scientific research progress rather than a financial or regulatory filing. It is relatively short (2288 characters) and does not contain financial data or detailed report content. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) since it is a miscellaneous company announcement that does not fit other categories.
2008-09-17 English
Preliminary Final Report 20 pages ?Kb
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report For the year ended 30 June 2008' and contains detailed financial statements including income statement, balance sheet, statement of changes in equity, and cash flow statement for the full fiscal year ended 30 June 2008. It includes comprehensive financial data and notes on accounting policies, indicating it is a full annual financial report. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are equivalent to annual reports or 10-K filings in other jurisdictions. The document is lengthy (15,000 characters) and contains substantive financial data, not just an announcement or certification. Therefore, it should be classified as an Annual Report (10-K equivalent). FY 2008
2008-08-26 English
Genes Identified 2 pages ?Kb
Regulatory Filings
2008-07-15 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and includes detailed consolidated statement of cash flows, cash reconciliation, financing activities, and compliance statements. It is a quarterly report with actual financial data for the quarter ended 30 June 2008. The presence of substantive financial data and the quarterly period indicates this is a financial report for a period shorter than a full fiscal year. The document is not an announcement or a certification but a full quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2008
2008-07-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.